charge, outlook cautious (trading +0.84%) Oriflame Q2 good, Russia/Baltic business light, falling consultants will weigh on name (trading -4.5%) Moller Maersk Q2 EBITDA & revs inline, raising FY guidance, mainly in Maersk line EFTA00406719 (trading +1.0%) Astrazeneca ups guidance after selling Nexium rights to Pfiz